Acro Pharmaceutical Services

Belkins
Acro Pharmaceutical Services (Acro) dispenses specialty medications directly to physician offices and to patients’ homes throughout the United States. The prescription drugs that Acro dispenses typically require special handling, clinical and financial support services. The cost of these specialty medications is much higher than those dispensed through retail pharmacies. Acro Pharmaceutical Services offers online pharmacy services such as prescription refills, prior authorization forms, and other services to assist the patient and provider. There are a growing number of specialty drugs available to patients. These specialty medications often focus on, but are not limited to, specific disease states such as Multiple Sclerosis, Psoriasis, Rheumatoid Arthritis, growth hormone deficiency, blood clotting disorders, types of cancer, pulmonary diseases, addiction treatment, mental health disorders, gastrointestinal diseases, rare orphan diseases and many others.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

VIRPAX PHARMACEUTICALS ENGAGES TORREYA CAPITAL TO ADVISE ON GLOBAL PARTNERING EFFORTS

Torreya Capital, Virpax Pharmaceuticals | April 23, 2021

news image

Virpax® Pharmaceuticals, Inc. reported today that it has appointed Torreya Capital, LLC as the Company's sole financial adviser for its partnering and licensing activities in strategic global markets. Torreya is a leading investment bank that has supported more than $100 billion in life sciences transactions since its establishment in 2007. “We are thrilled to be collaborating with Torreya to extend our partnerships in key markets,” said Anthony ...

Read More

FDA STUDY ASKS WHETHER DRUG NAMES CHANGE HOW CONSUMERS, DOCS VIEW MEDS

FiercePharma | January 22, 2020

news image

The FDA wants to know what, exactly, is in a drug name. Specifically, can a brand moniker determine how consumers and healthcare providers perceive the drug? So, the agency has launched a study to determine whether names sway opinions about a drug's effectiveness. Drugmakers submit their proposed names to the FDA for approval, but the companies often hire branding agencies to help create a name. The agency’s job is to make up brand names that draw relevant connections but follow FDA gu...

Read More

BUSINESS INSIGHTS

INDEX PHARMACEUTICALS STRENGTHENS THE CLINICAL DEVELOPMENT ORGANIZATION IN PREPARATION OF THE START OF THE PHASE III STUDY CONCLUDE WITH COBITOLIMOD

InDex Pharmaceuticals | August 23, 2021

news image

InDex Pharmaceuticals Holding AB today announced that two new employees have been appointed in the clinical development organisation in preparation of the start of the phase III study CONCLUDE with cobitolimod. Anders Bröijersén is joining InDex as Senior Medical Director Clinical Operations and Johan Levin as Project Manager Clinical Operations. Anders Bröijersén is a medical doctor and PhD with 15 years of experience in Clinical Development...

Read More

PHARMACY MARKET

LILLY AND LYCIA THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP NOVEL LYSOSOMAL TARGETING CHIMERA (LYTAC) DEGRADERS

Eli Lilly and Company | August 25, 2021

news image

Eli Lilly and Company and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia's proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology. Lycia uses its next-generation degradation approach to target the untapped extracellular proteome, including cell surface receptors and secreted proteins. The LYTAC p...

Read More

BUSINESS INSIGHTS

Torreya Capital, Virpax Pharmaceuticals | April 23, 2021

news image

VIRPAX PHARMACEUTICALS ENGAGES TORREYA CAPITAL TO ADVISE ON GLOBAL PARTNERING EFFORTS

Virpax® Pharmaceuticals, Inc. reported today that it has appointed Torreya Capital, LLC as the Company's sole financial adviser for its partnering and licensing activities in strategic global markets. Torreya is a leading investment bank that has supported more than $100 billion in life sciences transactions since its establishment in 2007. “We are thrilled to be collaborating with Torreya to extend our partnerships in key markets,” said Anthony ...

Read More

FiercePharma | January 22, 2020

news image

FDA STUDY ASKS WHETHER DRUG NAMES CHANGE HOW CONSUMERS, DOCS VIEW MEDS

The FDA wants to know what, exactly, is in a drug name. Specifically, can a brand moniker determine how consumers and healthcare providers perceive the drug? So, the agency has launched a study to determine whether names sway opinions about a drug's effectiveness. Drugmakers submit their proposed names to the FDA for approval, but the companies often hire branding agencies to help create a name. The agency’s job is to make up brand names that draw relevant connections but follow FDA gu...

Read More

BUSINESS INSIGHTS

InDex Pharmaceuticals | August 23, 2021

news image

INDEX PHARMACEUTICALS STRENGTHENS THE CLINICAL DEVELOPMENT ORGANIZATION IN PREPARATION OF THE START OF THE PHASE III STUDY CONCLUDE WITH COBITOLIMOD

InDex Pharmaceuticals Holding AB today announced that two new employees have been appointed in the clinical development organisation in preparation of the start of the phase III study CONCLUDE with cobitolimod. Anders Bröijersén is joining InDex as Senior Medical Director Clinical Operations and Johan Levin as Project Manager Clinical Operations. Anders Bröijersén is a medical doctor and PhD with 15 years of experience in Clinical Development...

Read More

PHARMACY MARKET

Eli Lilly and Company | August 25, 2021

news image

LILLY AND LYCIA THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP NOVEL LYSOSOMAL TARGETING CHIMERA (LYTAC) DEGRADERS

Eli Lilly and Company and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia's proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology. Lycia uses its next-generation degradation approach to target the untapped extracellular proteome, including cell surface receptors and secreted proteins. The LYTAC p...

Read More